FMS-like tyrosine kinase 3 in normal hematopoiesis and acute myeloid leukemia

Bertrand W. Parcells, Alan K. Ikeda, Tiffany Simms-Waldrip, Theodore B. Moore, Kathleen M. Sakamoto

Research output: Contribution to journalArticle

70 Citations (Scopus)

Abstract

Ligand-mediated activation of the FMS-like tyrosine kinase 3 (FLT3) receptor is important for normal proliferation of primitive hematopoietic cells. However, activating mutations in FLT3 induce ligand-independent downstream signaling that promotes oncogenesis through pathways involved in proliferation, differentiation, and survival. FLT3 mutations are identified as the most frequent genetic abnormality in acute myeloid leukemia and are also observed in other leukemias. Multiple small-molecule inhibitors are under development to target aberrant FLT3 activity that confers a poor prognosis in patients.

Original languageEnglish (US)
Pages (from-to)1174-1184
Number of pages11
JournalStem Cells
Volume24
Issue number5
DOIs
StatePublished - May 2006

Fingerprint

Hematopoiesis
Acute Myeloid Leukemia
Protein-Tyrosine Kinases
Ligands
Mutation
Receptor Protein-Tyrosine Kinases
Carcinogenesis
Leukemia
Survival

Keywords

  • Acute myeloid leukemia
  • FMS-like tyrosine kinase 3
  • Hematopoiesis
  • Internal tandem duplication
  • Small molecule inhibitor

ASJC Scopus subject areas

  • Cell Biology

Cite this

FMS-like tyrosine kinase 3 in normal hematopoiesis and acute myeloid leukemia. / Parcells, Bertrand W.; Ikeda, Alan K.; Simms-Waldrip, Tiffany; Moore, Theodore B.; Sakamoto, Kathleen M.

In: Stem Cells, Vol. 24, No. 5, 05.2006, p. 1174-1184.

Research output: Contribution to journalArticle

Parcells, Bertrand W. ; Ikeda, Alan K. ; Simms-Waldrip, Tiffany ; Moore, Theodore B. ; Sakamoto, Kathleen M. / FMS-like tyrosine kinase 3 in normal hematopoiesis and acute myeloid leukemia. In: Stem Cells. 2006 ; Vol. 24, No. 5. pp. 1174-1184.
@article{c5907cda2bd04445b5c5e4bee7fe3760,
title = "FMS-like tyrosine kinase 3 in normal hematopoiesis and acute myeloid leukemia",
abstract = "Ligand-mediated activation of the FMS-like tyrosine kinase 3 (FLT3) receptor is important for normal proliferation of primitive hematopoietic cells. However, activating mutations in FLT3 induce ligand-independent downstream signaling that promotes oncogenesis through pathways involved in proliferation, differentiation, and survival. FLT3 mutations are identified as the most frequent genetic abnormality in acute myeloid leukemia and are also observed in other leukemias. Multiple small-molecule inhibitors are under development to target aberrant FLT3 activity that confers a poor prognosis in patients.",
keywords = "Acute myeloid leukemia, FMS-like tyrosine kinase 3, Hematopoiesis, Internal tandem duplication, Small molecule inhibitor",
author = "Parcells, {Bertrand W.} and Ikeda, {Alan K.} and Tiffany Simms-Waldrip and Moore, {Theodore B.} and Sakamoto, {Kathleen M.}",
year = "2006",
month = "5",
doi = "10.1634/stemcells.2005-0519",
language = "English (US)",
volume = "24",
pages = "1174--1184",
journal = "Stem Cells",
issn = "1066-5099",
publisher = "AlphaMed Press",
number = "5",

}

TY - JOUR

T1 - FMS-like tyrosine kinase 3 in normal hematopoiesis and acute myeloid leukemia

AU - Parcells, Bertrand W.

AU - Ikeda, Alan K.

AU - Simms-Waldrip, Tiffany

AU - Moore, Theodore B.

AU - Sakamoto, Kathleen M.

PY - 2006/5

Y1 - 2006/5

N2 - Ligand-mediated activation of the FMS-like tyrosine kinase 3 (FLT3) receptor is important for normal proliferation of primitive hematopoietic cells. However, activating mutations in FLT3 induce ligand-independent downstream signaling that promotes oncogenesis through pathways involved in proliferation, differentiation, and survival. FLT3 mutations are identified as the most frequent genetic abnormality in acute myeloid leukemia and are also observed in other leukemias. Multiple small-molecule inhibitors are under development to target aberrant FLT3 activity that confers a poor prognosis in patients.

AB - Ligand-mediated activation of the FMS-like tyrosine kinase 3 (FLT3) receptor is important for normal proliferation of primitive hematopoietic cells. However, activating mutations in FLT3 induce ligand-independent downstream signaling that promotes oncogenesis through pathways involved in proliferation, differentiation, and survival. FLT3 mutations are identified as the most frequent genetic abnormality in acute myeloid leukemia and are also observed in other leukemias. Multiple small-molecule inhibitors are under development to target aberrant FLT3 activity that confers a poor prognosis in patients.

KW - Acute myeloid leukemia

KW - FMS-like tyrosine kinase 3

KW - Hematopoiesis

KW - Internal tandem duplication

KW - Small molecule inhibitor

UR - http://www.scopus.com/inward/record.url?scp=33747332700&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33747332700&partnerID=8YFLogxK

U2 - 10.1634/stemcells.2005-0519

DO - 10.1634/stemcells.2005-0519

M3 - Article

C2 - 16410383

AN - SCOPUS:33747332700

VL - 24

SP - 1174

EP - 1184

JO - Stem Cells

JF - Stem Cells

SN - 1066-5099

IS - 5

ER -